科威特 COVID-19 大流行之前和期间从一家二级医院分离的临床大肠埃希菌和铜绿假单胞菌的抗菌药耐药性模式。

IF 1.7 Q3 INFECTIOUS DISEASES GERMS Pub Date : 2022-09-30 eCollection Date: 2022-09-01 DOI:10.18683/germs.2022.1341
Walid Q Alali, Naglaa M Abdo, Wadha AlFouzan, Rita Dhar
{"title":"科威特 COVID-19 大流行之前和期间从一家二级医院分离的临床大肠埃希菌和铜绿假单胞菌的抗菌药耐药性模式。","authors":"Walid Q Alali, Naglaa M Abdo, Wadha AlFouzan, Rita Dhar","doi":"10.18683/germs.2022.1341","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The study objective was to compare the prevalence of antimicrobial resistance (AMR) in clinical <i>Escherichia coli</i> and <i>Pseudomonas aeruginosa</i> isolates obtained from a secondary-care hospital prior to and during the COVID-19 pandemic in Kuwait.</p><p><strong>Methods: </strong>A retrospective descriptive study was conducted based on AMR profiles of clinical Escherichia coli and Pseudomonas aeruginosa isolates. The AMR data represented isolates from five specimen types (body fluids; blood; respiratory; wound, bone, or other tissues; and urine) of patients admitted to four wards (surgical, medical, pediatric, and maternal-postnatal). Tested isolates between January 2019 and February 2020 represented the pre-COVID-19 pandemic period in Kuwait, whereas those from February 2020 until April 2021 represented the 'during COVID-19' period.</p><p><strong>Results: </strong>A total of 1,303 isolates (57.2% <i>E. coli</i> and 42.8% <i>P. aeruginosa</i>) were analyzed. For ceftazidime, ertapenem and meropenem, the prevalence of AMR in <i>E. coli</i> was significantly (p<0.05) lower in pre-COVID-19 wards compared to that during COVID-19, whereas for other antibiotics (i.e., cefepime, gentamicin, and trimethoprim/sulfamethoxazole), the prevalence of AMR in pre-COVID-19 was significantly higher than that during COVID-19. The prevalence of AMR to gentamicin in <i>P. aeruginosa</i> isolates from non-COVID-19 wards (52.8%) was significantly higher (p<0.001) than that from COVID-19 wards (35.0%) and from the pre-COVID-19 period (32.9%). The multidrug-resistance (MDR) prevalence was 37.4% for <i>E. coli</i> and 32.1% for <i>P. aeruginosa</i> isolates. The odds of MDR in <i>E. coli</i> isolates from the COVID-19 medical wards were significantly lower (OR=0.27, [95%CI: 0.09-0.80], p=0.018) compared to the pre-COVID-19 wards. The odds of MDR <i>E. coli</i> and <i>P. aeruginosa</i> isolates by COVID-19 status stratified by specimen type were not different (p>0.05).</p><p><strong>Conclusions: </strong>No major differences in AMR in <i>E. coli</i> and <i>P. aeruginosa</i> prevalence by specimen type and wards prior to and during the COVID-19 pandemic was observed at this hospital. The high reported MDR prevalence calls for better infection control and prevention.</p>","PeriodicalId":45107,"journal":{"name":"GERMS","volume":null,"pages":null},"PeriodicalIF":1.7000,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482471/pdf/germs-12-03-372.pdf","citationCount":"0","resultStr":"{\"title\":\"Antimicrobial resistance pattern in clinical <i>Escherichia coli</i> and <i>Pseudomonas aeruginosa</i> isolates obtained from a secondary-care hospital prior to and during the COVID-19 pandemic in Kuwait.\",\"authors\":\"Walid Q Alali, Naglaa M Abdo, Wadha AlFouzan, Rita Dhar\",\"doi\":\"10.18683/germs.2022.1341\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The study objective was to compare the prevalence of antimicrobial resistance (AMR) in clinical <i>Escherichia coli</i> and <i>Pseudomonas aeruginosa</i> isolates obtained from a secondary-care hospital prior to and during the COVID-19 pandemic in Kuwait.</p><p><strong>Methods: </strong>A retrospective descriptive study was conducted based on AMR profiles of clinical Escherichia coli and Pseudomonas aeruginosa isolates. The AMR data represented isolates from five specimen types (body fluids; blood; respiratory; wound, bone, or other tissues; and urine) of patients admitted to four wards (surgical, medical, pediatric, and maternal-postnatal). Tested isolates between January 2019 and February 2020 represented the pre-COVID-19 pandemic period in Kuwait, whereas those from February 2020 until April 2021 represented the 'during COVID-19' period.</p><p><strong>Results: </strong>A total of 1,303 isolates (57.2% <i>E. coli</i> and 42.8% <i>P. aeruginosa</i>) were analyzed. For ceftazidime, ertapenem and meropenem, the prevalence of AMR in <i>E. coli</i> was significantly (p<0.05) lower in pre-COVID-19 wards compared to that during COVID-19, whereas for other antibiotics (i.e., cefepime, gentamicin, and trimethoprim/sulfamethoxazole), the prevalence of AMR in pre-COVID-19 was significantly higher than that during COVID-19. The prevalence of AMR to gentamicin in <i>P. aeruginosa</i> isolates from non-COVID-19 wards (52.8%) was significantly higher (p<0.001) than that from COVID-19 wards (35.0%) and from the pre-COVID-19 period (32.9%). The multidrug-resistance (MDR) prevalence was 37.4% for <i>E. coli</i> and 32.1% for <i>P. aeruginosa</i> isolates. The odds of MDR in <i>E. coli</i> isolates from the COVID-19 medical wards were significantly lower (OR=0.27, [95%CI: 0.09-0.80], p=0.018) compared to the pre-COVID-19 wards. The odds of MDR <i>E. coli</i> and <i>P. aeruginosa</i> isolates by COVID-19 status stratified by specimen type were not different (p>0.05).</p><p><strong>Conclusions: </strong>No major differences in AMR in <i>E. coli</i> and <i>P. aeruginosa</i> prevalence by specimen type and wards prior to and during the COVID-19 pandemic was observed at this hospital. The high reported MDR prevalence calls for better infection control and prevention.</p>\",\"PeriodicalId\":45107,\"journal\":{\"name\":\"GERMS\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2022-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10482471/pdf/germs-12-03-372.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"GERMS\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18683/germs.2022.1341\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"GERMS","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18683/germs.2022.1341","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

摘要

简介研究目的是比较科威特 COVID-19 大流行之前和期间从一家二级医院分离的临床大肠埃希菌和铜绿假单胞菌的抗菌药耐药性(AMR)流行情况:根据临床大肠埃希菌和铜绿假单胞菌分离物的 AMR 图谱进行了一项回顾性描述研究。AMR 数据来自四个病房(外科、内科、儿科和产后)收治病人的五种标本类型(体液、血液、呼吸道、伤口、骨骼或其他组织以及尿液)的分离物。2019 年 1 月至 2020 年 2 月期间检测的分离物代表科威特的 "COVID-19 前 "大流行时期,而 2020 年 2 月至 2021 年 4 月期间检测的分离物代表 "COVID-19 期间":结果:共分析了 1,303 个分离株(57.2% 为大肠杆菌,42.8% 为铜绿假单胞菌)。就头孢他啶、厄他培南和美罗培南而言,来自非COVID-19病房(52.8%)的大肠杆菌和铜绿假单胞菌分离株的AMR发生率分别为32.1%和32.1%,而来自非COVID-19病房(52.8%)的大肠杆菌和铜绿假单胞菌分离株的AMR发生率分别为32.1%和32.1%。与 COVID-19 前的病房相比,COVID-19 医疗病房的大肠杆菌分离物中 MDR 的几率明显降低(OR=0.27,[95%CI:0.09-0.80],p=0.018)。按标本类型分层的 COVID-19 状态下 MDR 大肠杆菌和铜绿假单胞菌分离物的几率没有差异(P>0.05):该医院在 COVID-19 大流行之前和期间,按标本类型和病房划分的大肠杆菌和铜绿假单胞菌的 AMR 感染率没有重大差异。报告的 MDR 感染率较高,因此需要加强感染控制和预防。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Antimicrobial resistance pattern in clinical Escherichia coli and Pseudomonas aeruginosa isolates obtained from a secondary-care hospital prior to and during the COVID-19 pandemic in Kuwait.

Introduction: The study objective was to compare the prevalence of antimicrobial resistance (AMR) in clinical Escherichia coli and Pseudomonas aeruginosa isolates obtained from a secondary-care hospital prior to and during the COVID-19 pandemic in Kuwait.

Methods: A retrospective descriptive study was conducted based on AMR profiles of clinical Escherichia coli and Pseudomonas aeruginosa isolates. The AMR data represented isolates from five specimen types (body fluids; blood; respiratory; wound, bone, or other tissues; and urine) of patients admitted to four wards (surgical, medical, pediatric, and maternal-postnatal). Tested isolates between January 2019 and February 2020 represented the pre-COVID-19 pandemic period in Kuwait, whereas those from February 2020 until April 2021 represented the 'during COVID-19' period.

Results: A total of 1,303 isolates (57.2% E. coli and 42.8% P. aeruginosa) were analyzed. For ceftazidime, ertapenem and meropenem, the prevalence of AMR in E. coli was significantly (p<0.05) lower in pre-COVID-19 wards compared to that during COVID-19, whereas for other antibiotics (i.e., cefepime, gentamicin, and trimethoprim/sulfamethoxazole), the prevalence of AMR in pre-COVID-19 was significantly higher than that during COVID-19. The prevalence of AMR to gentamicin in P. aeruginosa isolates from non-COVID-19 wards (52.8%) was significantly higher (p<0.001) than that from COVID-19 wards (35.0%) and from the pre-COVID-19 period (32.9%). The multidrug-resistance (MDR) prevalence was 37.4% for E. coli and 32.1% for P. aeruginosa isolates. The odds of MDR in E. coli isolates from the COVID-19 medical wards were significantly lower (OR=0.27, [95%CI: 0.09-0.80], p=0.018) compared to the pre-COVID-19 wards. The odds of MDR E. coli and P. aeruginosa isolates by COVID-19 status stratified by specimen type were not different (p>0.05).

Conclusions: No major differences in AMR in E. coli and P. aeruginosa prevalence by specimen type and wards prior to and during the COVID-19 pandemic was observed at this hospital. The high reported MDR prevalence calls for better infection control and prevention.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
GERMS
GERMS INFECTIOUS DISEASES-
CiteScore
2.80
自引率
5.00%
发文量
36
期刊最新文献
Aggregatibacter actinomycetemcomitans endocarditis in an adult patient with patent ductus arteriosus. Clinical spectrum of extrapulmonary non-tuberculous mycobacterial disease in immunocompetent patients: a case series. Clinical, epidemiological and molecular aspects of patients with mpox in Romania. Continuous versus intermittent infusion of beta-lactam antibiotics: where do we stand today? A narrative review. Infective endocarditis by carbapenem-resistant Gram-negative bacteria - a systematic review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1